ESBRIET
What it isTGF-beta-modulating antifibrotic; idiopathic pulmonary fibrosis.
Why this oneUnlike nintedanib, its tolerability profile centers on photosensitivity and appetite or weight loss rather than diarrhea.
What limits itGI upset, weight loss and photosensitivity limit use; monitor liver tests. CYP1A2 interactions matter, and smoking lowers exposure.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Idiopathic pulmonary fibrosis | Adult | 267 mg TID | 801 mg TID (2,403 mg/day) | 2,403 mg/day |
Titration Days 1-7: 267 mg TID; days 8-14: 534 mg TID; day 15 onward: 801 mg TID
Renal Use with caution in mild/moderate/severe impairment; not recommended in ESRD on dialysis
Hepatic Use with caution in mild/moderate (Child-Pugh A/B); not recommended in severe (Child-Pugh C)
Pregnancy Insufficient human data; not teratogenic in animals.
Lactation No information on presence in human milk.
NO BOXED WARNINGS
Principal riskPhotosensitivity and weight loss
Cost, est. cash$100–$5,000/month
Generic entry2022
Legacy pregnancy categoryC
Defining liabilitySerious infection, cytopenias, hepatic injury and malignancy risk require laboratory and clinical monitoring.

Open Pirfenidone in the interactive console ↗

